Dashboard
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
- Poor long term growth as Net Sales has grown by an annual rate of -0.98% and Operating profit at 8.31% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.54
Flat results in Jun 25
Risky - Negative EBITDA
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
USD 9 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-1.14
167.00%
-1.27
Total Returns (Price + Dividend) 
Avalon GloboCare Corp. for the last several years.
Risk Adjusted Returns v/s 
News
Is Avalon GloboCare Corp. technically bullish or bearish?
As of 5 September 2025, the technical trend for Avalon GloboCare Corp. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and KST show mildly bullish signals. Bollinger Bands are bearish on the weekly and mildly bearish on the monthly. The Dow Theory indicates a bearish trend on the monthly, with no trend on the weekly. There is no available return data to compare the company's performance against the S&P 500....
Read MoreIs Avalon GloboCare Corp. overvalued or undervalued?
As of 23 May 2017, Avalon GloboCare Corp. moved from a grade of does not qualify to risky. The company is overvalued given its negative financial metrics, including a Price to Book Value of -1.66 and an EV to EBITDA ratio of -2.64, indicating significant financial distress. Additionally, the Return on Capital Employed (ROCE) stands at a troubling -180.71%, further underscoring the company's challenges. In comparison to its peers, Avalon GloboCare Corp. shows a less favorable position with a P/E ratio of -0.7611, while CohBar, Inc. holds a more attractive valuation with an EV to EBITDA of 0.8535. Atreca, Inc. is also in a precarious position with a P/E of -0.0467. Although specific return data is not available, the lack of positive performance metrics suggests that Avalon GloboCare Corp. is not keeping pace with broader market benchmarks like the S&P 500....
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 3 Schemes (0.9%)
Held by 4 Foreign Institutions (0.12%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
QoQ Growth in quarter ended Jun 2025 is 33.33% vs 0.00% in Mar 2025
QoQ Growth in quarter ended Jun 2025 is -440.00% vs 7.41% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 0.00% vs 8.33% in Dec 2023
YoY Growth in year ended Dec 2024 is 52.69% vs -40.34% in Dec 2023






